We have located links that may give you full text access.
M1 UK Streptococcus pyogenes causing community-acquired pneumonia, pleural empyema and streptococcal toxic shock syndrome.
Journal of Global Antimicrobial Resistance 2024 March 28
OBJECTIVES: Streptococcus pyogenes causes superficial infections, but can also cause deep-seated infections and toxin-mediated diseases. In the present study, phylogenetic and in silico prediction analyses were performed on an antimicrobial-resistant M1UK S. pyogenes strain causing severe clinical manifestations during the current surge of invasive group A Streptococcus (iGAS) disease.
PATIENT AND METHODS: A 40-year-old patient was admitted to the hospital with fever, chest pain, and fatigue. Based on the clinical and laboratory findings a diagnosis of sepsis with disseminated intravascular coagulation, community-acquired pneumonia, pleural empyema and streptococcal toxic shock syndrome was made. Microbial identification was performed by multiplex PCR and conventional culturing. Furthermore, antimicrobial susceptibility testing, whole genome sequencing, phylogenomic analysis, and in silico prediction analysis of antimicrobial resistance genes and virulence factors were performed.
RESULTS: S. pyogenes isolates were detected in pleural fluid and sputum of the patient. Both isolates belonged to the M1UK lineage of the emm1/ST28 clone, being closely related with an M1UK GAS strain from Australia. They exhibited resistance to erythromycin and clindamycin, and susceptibility-increased exposure to levofloxacin and carried genes encoding for protein homologues of antibiotic efflux pumps. Moreover, several virulence factors, and a previously described single-nucleotide polymorphism in the 5' transcriptional leader sequence of the ssrA gene, which enhances expression of SpeA, were detected.
CONCLUSIONS: The present antimicrobial-resistant M1UK S. pyogenes strain represents the first report of this emerging lineage associated with such manifestations of iGAS disease.
PATIENT AND METHODS: A 40-year-old patient was admitted to the hospital with fever, chest pain, and fatigue. Based on the clinical and laboratory findings a diagnosis of sepsis with disseminated intravascular coagulation, community-acquired pneumonia, pleural empyema and streptococcal toxic shock syndrome was made. Microbial identification was performed by multiplex PCR and conventional culturing. Furthermore, antimicrobial susceptibility testing, whole genome sequencing, phylogenomic analysis, and in silico prediction analysis of antimicrobial resistance genes and virulence factors were performed.
RESULTS: S. pyogenes isolates were detected in pleural fluid and sputum of the patient. Both isolates belonged to the M1UK lineage of the emm1/ST28 clone, being closely related with an M1UK GAS strain from Australia. They exhibited resistance to erythromycin and clindamycin, and susceptibility-increased exposure to levofloxacin and carried genes encoding for protein homologues of antibiotic efflux pumps. Moreover, several virulence factors, and a previously described single-nucleotide polymorphism in the 5' transcriptional leader sequence of the ssrA gene, which enhances expression of SpeA, were detected.
CONCLUSIONS: The present antimicrobial-resistant M1UK S. pyogenes strain represents the first report of this emerging lineage associated with such manifestations of iGAS disease.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app